KalVista Initiates Phase 1 Clinical Trial for HAE Treatment

KalVista Pharmaceuticals announces the dosing of the first subject in a first-in-human clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally delivered KVD818 in healthy volunteers. A KalVista discovery, KVD818 is a novel, potent, and selective inhibitor of plasma kallikrein in development for the prevention of attacks of edema in patients with HAE.

Andrew Crockett, KalVista’s CEO, said: “The successful dosing of the first subject in this first-in-human clinical trial is an important milestone for the KVD818 development program and a first step in our goal of developing a best in class oral plasma kallikrein inhibitor for HAE. We believe that an oral drug for the treatment of HAE will be an important advancement for patients who suffer from this condition.”

This first clinical study will provide data to evaluate the key characteristics of safety, drug exposure and bioactivity (plasma kallikrein inhibition) achieved after oral dosing of KVD818. This clinical trial is being conducted in the United Kingdom and the results of this study are expected to be announced in the first half of 2017. If the Phase 1 program achieves its goals, KalVista plans to initiate a Phase 2 trial in HAE patients.
(Source: KalVista)

2016-08-11T23:34:17+00:00